Please login to the form below

Not currently logged in
Email:
Password:

lung disease

This page shows the latest lung disease news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance. The new partnership will focus on creating an AAV for lung disease. ... AstraZeneca’s push into genetic therapies has stepped up a gear, thanks to a collaboration with 4D Molecular Therapeutics on a new

Latest news

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    exacerbations – a sudden worsening of symptoms – in moderate to very severe chronic obstructive pulmonary disease (COPD) patients. ... as lung function scores.

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    such as asthma, nasal polyps and chronic obstructive pulmonary disease (COPD) “means there is a remarkably broad and deep pipeline within Dupixent itself”. ... quickly, as well as a challenge moving into more fiercely-fought categories like non-small

  • Roche’s lung drug Esbriet reserved for worse cases, says NICE Roche’s lung drug Esbriet reserved for worse cases, says NICE

    to wait until their disease has progressed and lung function has deteriorated before they can get access to the drug. ... IPF is a progressive, irreversible and typically fatal lung disease characterised by scarring pf the lungs that makes breathing

  • FDA panel rejects Aradigm/Grifols’ inhaled antibiotic FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

    Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease. ... NCFBE is a severe, chronic and rare disease characterised

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    COPD is a serious lung disease that affects millions of people, ”commented Eric Dube, head of GSK’s respiratory business unit.

More from news
Approximately 3 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... However, Insmed

  • Pharma deals during August 2014 Pharma deals during August 2014

    lung scarring condition for which there are no approved drugs in the US. ... It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    for idiopathic pulmonary fibrosis (IPF) – a rare lung disease, characterised by by the formation of scar tissue within the lungs, that has nearly as bad a prognosis as lung cancer and ... This is in addition to nintedanib's potential as an oncology

  • Denmark: rising pharma spend amid healthcare cost-containment Denmark: rising pharma spend amid healthcare cost-containment

    Although patient choice is enshrined in law, care pathways particularly for cancer and heart disease were also created to ensure consistent treatment nationwide and reduce health inequalities. ... Thus, the top three causes of death in Denmark are

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    3. Coronary heart disease. 4. Lung cancer. 5. Stomach cancer. 6. ... Emergency care services are inundated with patients seeking routine treatments, and chronic disease management and preventative care are not so good.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics